Paradigm’s Chief Medical Officer, Dr Donna Skerrett, delivered an oral presentation at the 2026 OARSI Congress in the US, highlighting Phase 2 (PARA_OA_008) biomarker data for iPPS in knee osteoarthritis. The data, also published in Arthritis Research & Therapy, demonstrated reductions in markers of cartilage degradation, inflammation and pain, with correlations to clinical outcomes. These findings provide further mechanistic support for Paradigm’s ongoing Phase 3 program.